GlaxoSmithKline has signed an agreement for worldwide strategic alliance with Santaris Pharma for the discovery, development and commercialisation of novel medicines against viral diseases. This alliance is worth more than $700 million.
Santaris Pharma will receive an upfront fee of $3 million for the first antiviral programme, while GSK would make an equity investment of US $5 million in Santaris Pharma. If candidate drugs from the first viral target programme are successful and reach the market, GSK could make additional milestone payments of up to $140m to Santaris Pharma. Similar upfront payments and milestones are payable by GSK to Santaris Pharma in respect of each of the further three antiviral programmes, if GSK elects to initiate these additional programmes in the collaboration.
In addition, if GSK exercises its option to further develop and commercialise SPC3649, it will make a further up front payment of $5 million and additional milestones of up to $122m if the drug obtains regulatory approvals in Europe and the USA. Overall, under the collaboration Santaris Pharma could be eligible to receive in excess of $700m in upfront fees and development and regulatory milestones payments. If a product is successfully commercialised, Santaris Pharma will receive high single to double-digit royalties on worldwide sales of alliance products.
The collaboration provides GSK access to patented RNA antagonist compounds, based on Santaris Pharma's unique Locked Nucleic Acid technology, for development as potential new therapies for selected viral diseases.
GlaxoSmithKline will participate in the alliance through its Infectious Diseases Centre of Excellence for Drug Discovery (ID CEDD). Under the terms of the agreement, Santaris Pharma will grant GSK options to drug candidates discovered and developed under the collaboration in up to four different viral disease programmes. In each of these R&D programmes, Santaris Pharma will be responsible for the discovery and development of RNA antagonist drug candidates through to completion of phase IIa ("Clinical Proof of Concept"), at which point GSK has an exclusive option to license each compound for further development and commercialisation on a worldwide basis. GSK also has an option to include as an additional programme in the collaboration, SPC3649, Santaris Pharma's preclinical LNA-antimiR against micro RNA-122, which is being developed by Santaris Pharma as a potential new therapy for Hepatitis C infection.
Announcing the collaboration, Dr Henrik Ørum, Santaris Pharma's chief scientific officer and VP Business Development commented, "We are delighted that GlaxoSmithKline has chosen to collaborate with Santaris Pharma in the RNA medicines field. We are confident that the high potency and exquisite precision of RNA targeting achievable by LNA oligonucleotides has the potential to achieve clinical breakthroughs in viral infections. I can think of no stronger partner for Santaris Pharma in infectious disease research than GSK."
Dr Zhi Hong, senior vice president and head, GlaxoSmithKline's ID CEDD said, "The Locked Nucleic Acid technology platform developed by Santaris Pharma has the potential to transform Gene Interference therapies. We are facing numerous challenges in infectious disease areas where tractable targets are limiting. Innovative medicines with unprecedented mechanisms of action are lacking. This alliance has the ability to accelerate our drug discovery programmes against multiple infectious disease targets."
LNA is an analogue of RNA (ribonucleic acid). The conformation of the ribose sugar in LNA is 'locked' in the RNA shape by virtue of its rigid bicyclic structure. The result is that when incorporated into oligonucleotides, LNA conveys dramatically enhanced binding affinity to complementary RNA sequences. Each monomer unit of LNA incorporated into a DNA oligonucleotide increases binding affinity by approximately ten-fold.